Nicox S.A. (LON:0RCQ)

Market Cap	14.03M
Revenue (ttm)	3.07M
Net Income (ttm)	-14.91M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117
Average Volume	913
Open	0.2250
Previous Close	0.2235
Day's Range	0.2250 - 0.2260
52-Week Range	0.1650 - 0.3300
Beta	0.89
RSI	49.88
Earnings Date	Jul 18, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2024, Nicox's revenue was 8.43 million, an increase of 18.31% compared to the previous year's 7.13 million. Losses were -22.39 million, 7.23% more than in 2023.

Financial numbers in EUR